作者@article {faughtp3.5 - 022 ={爱德华Faught宣李和崔Jiyoon Manoj Malhotra和拉塞尔·l·Knoth}, title ={住院病人住院治疗风险Perampanel治疗前后患者癫痫(p3.5 - 022)},体积={92}={15}补充数量,elocation-id = {p3.5 - 022} ={2019},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:探讨住院病人住院治疗风险Perampanel启动后癫痫患者。首页背景:Perampanel,非竞争性AMPA谷氨酸受体拮抗剂,被批准治疗部分性癫痫的儿童和成人癫痫患者4岁及以上,以及辅助治疗主要广义tonic-clonic发作癫痫患者12岁及以上。设计/方法:交响曲健康,具有全国代表性的医学和药学数据库,被用于这项研究。患者发现如果他们填补了perampanel处方2014年7月到2016年6月期间。索引日期的日期的第一个填充药物。患者选择如果他们4 {\ textendash} 11岁与任何部分性(焦)癫痫(POS),或12岁或以上程度,任何POS或任何主要广义主音{\ textendash}阵发性发作(gtc),并连续观察一段这个日期之前还是之后。感兴趣的结果变量是为期一年的所有原因和epilepsy-related perampanel启动后住院病人的住院治疗的相对风险。结果:1771例患者纳入本研究。平均年龄33岁,55 \ %是女性。预先索引时期相比,post-perampanel时期与住院病人住院的风险显著降低。一年期全因住院病人住院治疗风险比为0.76 (p \ < 0.05),和36.2 \ %的风险在预先索引相比一年随访29.5 \ %。同样,一年期epilepsy-related住院病人住院治疗风险比为0.72 (p \ < 0.05),和30.8 \ %预先索引期间,相比23.9 \ %在随访期间。结论:癫痫患者,治疗perampanel,相对于一年期时期perampanel启动之前,与显著减少一年期全因和epilepsy-related住院病人住院治疗风险。Disclosure: Dr. Faught has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with As a KOL for Eisai inc. Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc. Dr. Choi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Inc. Dr. Malhotra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc. Dr. Knoth has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/92/15_Supplement/P3.5-022}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }